Bioinformatic Identification of TP53 Gene Mutation Hotspots in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.
Abstract
Mutations and inactivation of the TP53 gene are frequently observed in various types of malignancies. Precise knowledge of the genetic structure and detection of mutation hotspots are crucial, as these indicate a high probability of developing cancer. The aim of our study was to perform the bioinformatic detection of mutation hotspots in the TP53 gene in patients diagnosed with malignant colon neoplasms using self-developed software (version 1). We compared TP53 gene sequences from 50 healthy individuals with those from 50 patients diagnosed with colorectal carcinoma. Of the 50 samples from cancer patients, the most frequent mutations were observed in exons 5 and 8 (12 mutations per exon) and gene sequences of 12 samples, which differed from those of the 50 samples from healthy individuals. Based on our results, the distribution of mutations in the TP53 gene structure was not even across different exons. By comparing the gene sequences of healthy individuals with those of colon cancer samples, we conclude that structural changes occurring in similar gene regions are not associated with increases in susceptibility to malignancies in every case, namely, that the pathological mechanism is multifactorial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function mutations in the tumor suppressor genes TP53 (mutated in 50–60% of CRCs) and SMAD4 (mutated in ~15% of CRCs) also occur frequently [13,16].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Loss-of-function mutations in the tumor suppressor genes TP53 (mutated in 50–60% of CRCs) and SMAD4 (mutated in ~15% of CRCs) also occur frequently [13,16].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biopython: freely available python tools for computational molecular biology and bioinformatics
Cock, P. J. A., Antao, T., Chang, J. T., Chapman, B. A., Cox, C. J., Dalke, A., Friedberg, I., Hamelryck, T., Kauff, F., Wilczynski, B., et al. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp163 · Cited by 6,080 · cited 3×
“…chain is more vulnerable and sensitive at these points, which might increase the likelihood of mutations appearing in these regions [10–12]. the polynucleotide chain more vulnerable and sensitive at these points, which might increase the likelihood of mutations appearing in these regions [10–12].”
BackgroundLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Mutations often occur in breast cancer, lung cancer, Li–Fraumeni syndrome, and colorectal carcinoma [7].”
BackgroundChang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808 · cited 1×
“Furthermore, the very common mutation c.818G>C (rs28934576), appearing in exon 8, has been observed in breast, pancreatic, prostate, and pulmonary adenocarcinomas, which is also related to Li–Fraumeni syndrome [20,21].”
BackgroundWhy are there hotspot mutations in the TP53 gene in human cancers?
Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R. A., & Chan, C. S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.180 · Cited by 607
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589 · cited 1×
“Furthermore, the very common mutation c.818G>C (rs28934576), appearing in exon 8, has been observed in breast, pancreatic, prostate, and pulmonary adenocarcinomas, which is also related to Li–Fraumeni syndrome [20,21].”
BackgroundTP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408 · cited 1×
“Most mutations occurring in the TP53 gene are missense mutations that lead to the synthesis of a p53 protein with a malformed structure that will be unable to fulfil its function, allowing the uncontrolled proliferation of cells carrying mutated and damaged DNA [4–6].”
Backgroundp53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
Li, X.-L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.84 · Cited by 367 · cited 2×
“Most mutations occurring in the TP53 gene are missense mutations that lead to the synthesis of a p53 protein with a malformed structure that will be unable to fulfil its function, allowing the uncontrolled proliferation of cells carrying mutated and damaged DNA [4–6].”
BackgroundTumor-Suppressor Functions of the TP53 Pathway
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 327 · cited 2×
“By regulating cell division, it prevents uncontrolled growth and proliferation in cells [1,3].”
BackgroundKotler, E., Shani, O., Goldfeld, G., Lotan-Pompan, M., Tarcic, O., Gershoni, A., Hopf, T. A., Marks, D. S., Oren, M., & Segal, E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.012 · Cited by 285 · cited 1×
“In addition, the alteration c.818G>A in exon 8, which seems to be a pathogenic variant, has also been described in the context of colorectal cancer [17,18].”
BackgroundLeroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1033 · Cited by 185 · cited 4×
“For ease of reading, we sorted the samples into two groups, i.e., those of healthy individuals [9] and those with colon cancer, and the TP53 gene mutations in these two groups were presented in two respective tables that were separated and categorized by individual exons (Figures 1 and 2).”
BackgroundMethodInfluentialLi, V. D., Li, K. H. L., & Li, J. T. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2817-z · Cited by 109 · cited 2×
“Consequently, this is one of the most common types of cancer in which somatic mutations of the TP53 gene can be observed, and several studies have shown that these TP53 mutations can be associated with an unfavorable prognosis and a high metastatic risk [8].”
BackgroundMethodHeterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations
Xu, J., Qian, J., Hu, Y., Wang, J., Zhou, X., Chen, H., & Fang, J.-Y. (2014) · Scientific Reports · doi:10.1038/srep04223 · Cited by 76
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
Dutta, S., Pregartner, G., Rücker, F. G., Heitzer, E., Zebisch, A., Bullinger, L., Berghold, A., Döhner, K., & Sill, H. (2020) · Cancers · doi:10.3390/cancers12030637 · Cited by 56 · cited 1×
“The mutations described in other malignancies comprise, for instance, the alteration c.1024C>T (rs730882029) in exon 10, which has been described in the context of acute myeloid leukemia [19].”
BackgroundLiu, Y., Xu, F., Wang, Y., Wu, Q., Wang, B., Yao, Y., Zhang, Y., Han‐Zhang, H., Ye, J., Zhang, L., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10625 · Cited by 32
Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition
Gurzu, S., Szentirmay, Z., Tóth, E., Bara, T., Bara, T., & Jung, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057699 · Cited by 27
Self-citationMutation analysis of 13 driver genes of colorectal cancer-related pathways in Taiwanese patients
Chang, Y. C., Chang, J., Liu, T., Lin, C., Yang, S.-F., Ho, C., Chen, W. T., & Chang, Y.-S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2314 · Cited by 22 · cited 3×
“…that the distribution of mutations in the TP53 gene structure cannot be considered even, since for certain exons, such as exons 5 (alterations in 12 samples) and 8 (alterations in 12 samples), structural di ff erences are far more frequent than those in other exons, such as exon 9, where we…”
BackgroundNatsume, H., Szczepaniak, K., Yamada, H., Iwashita, Y., Gędek, M., Šuto, J., Ishino, K., Kasajima, R., Matsuda, T., Manirakiza, F., et al. (2023) · Genes and Environment · doi:10.1186/s41021-022-00257-y · Cited by 20 · cited 1×
“These samples were collected in 2017 from patients treated at the hospital, and given the relatively challenging and costly sequencing of the TP53 gene, they were sequenced at Hamamatsu University in Japan [23,24].”
MethodSelf-citationManoharan, V., Karunanayake, E. H., Tennekoon, K. H., Silva, S. D., Imthikab, A. I. A., Silva, K. D., Angunawela, P., Vishwakula, S., & Lunec, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-6573-5 · Cited by 19 · cited 2×
“In addition, in exon 8, there is another frequent alteration, c.844C>T, which also seems to be pathogenic and appears in context with breast and colorectal cancer [15].”
BackgroundMaspin subcellular expression in wild-type and mutant TP53 gastric cancers
Gurzu, S., Jung, I., Sugimura, H., Staden, R. S., Yamada, H., Natsume, H., Iwashita, Y., Szodorai, R., & Szederjesi, J. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i7.741 · Cited by 18 · cited 1×
“By regulating cell division, it prevents uncontrolled growth and proliferation in cells [1,3].”
BackgroundSelf-citationFostira, F., Konstantopoulou, I., Mavroudis, D., Tryfonopoulos, D. J., Yannoukakos, D., & Voutsinas, G. E. (2014) · Clinical Genetics · doi:10.1111/cge.12397 · Cited by 10 · cited 1×
“Similarly, the c.637C>T mutation in exon 6 has been associated with both colorectal and breast cancers [15,16], highlighting the potential for shared mechanisms across different malignancies.”
BackgroundTP53 mutations in Romanian patients with colorectal cancer
Manirakiza, F., Yamada, H., Iwashita, Y., Ishino, K., Ishikawa, R., Kovács, Z., Osvath, E., Nzitakera, A., Gurzu, S., & Sugimura, H. (2023) · Genes and Environment · doi:10.1186/s41021-023-00277-2 · Cited by 5
Self-citationZampiga, V., Danesi, R., Tedaldi, G., Tebaldi, M., Cangini, I., Pirini, F., Pittureri, C., Amaducci, E., Guidi, L., Faedi, M., et al. (2016) · The International Journal of Biological Markers · doi:10.5301/jbm.5000227 · Cited by 4 · cited 1×
“For instance, the c.524G>A mutation in exon 5, which we identified as a frequent alteration, has been previously described as a driver mutation in colorectal cancer and Li–Fraumeni syndrome [12–14].”
BackgroundLiu, X., Feng, D., Huo, X., Xiao, X., & Chen, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8095 · Cited by 3 · cited 1×
“In addition, the alteration c.818G>A in exon 8, which seems to be a pathogenic variant, has also been described in the context of colorectal cancer [17,18].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Loss-of-function mutations in the tumor suppressor genes TP53 (mutated in 50–60% of CRCs) and SMAD4 (mutated in ~15% of CRCs) also occur frequently [13,16].”
Yuan, X., Xia, X., Li, J., & Zhao, G. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101591 · Cited by 3
Xia, X., Zhao, G., & Yuan, X. (2025) · Lecture notes in computer science · doi:10.1007/978-981-95-0698-9_1
Rapid Exploratory Data Visualization for Cancer Genomics
Regunath, K. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-4901-5_31
de Sousa, G. R., Carvalho, G. D. S., de Brito, B. M. I., da Silva, G., Lopes, M. C. R. B., Chagas, P. S., Valera, E. T., Cavalcanti, G. V., de Freitas, L. C. C., & Leopoldino, A. M. (2026) · Medical Oncology · doi:10.1007/s12032-026-03311-9
“LMSCC16 harbors two TP53 mutations, including a well characterized gain-function variant (p.R273H), previously reported in colorectal [29] and breast cancers [30] but not previously described in TSCC samples or cell lines.”
Metadata
- Authors
- Kovács, Z., Sugimura, H., György, T. A., Osvath, E., Manirakiza, F., & Gurzu, S.
- Affiliations
- Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș (RO)
- Sasaki Institute (JP)
- University of Rwanda (RW)
- Corresponding author
- Gurzu, Simona
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-06-15
- Volume
- 25
- Issue
- 12
- Pages
- 6612
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11203433
- OpenAlex
- W4399733078
- Cited by
- 5
- References
- 26
- Citations by year
- 2026: 2 · 2025: 3
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- TP53 gene, mutational hotspots, colorectal cancer, TP53 mutation, exon 5, exon 8, cancer susceptibility
- MeSH terms
- Aged, Exons, Female, Humans, Male, Middle Aged, Mutation, Colorectal Neoplasms, Tumor Suppressor Protein p53, Computational Biology, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.